Enfortumab vedotin is an antibody-drug conjugate that delivers the microtubule-disrupting agent monomethyl auristatin E (MMAE) to cells expressing Nectin-4. Enfortumab vedotin is FDA approved for bladder cancer.
This is a phase II, open-label, study to evaluate the efficacy, safety and tolerability of Enfortumab vedotin in participants with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
